Optometry Giving Sight and VOSH International played a leading role in developing an optometry school at the National Autonomous University in Managua, Nicaragua (UNAN). The five-year program graduated its first class in 2016 and produces approximately 30 new eye care professionals each year, with more than 220 educated to date. These graduates each care for approximately 4,000 people annually, providing nearly 900,000 more eye exams per year to the area.

Learn more HERE.

From June 2023, ZEISS MyoCare as the first age-related myopia management lens solution now is available in Canada. Years of research show that prevalences differ and the risks associated with progressive myopia require specific solutions for different target groups. The new ZEISS MyoCare lenses will become an essential building block in the management of progressive myopia.

Both myopia and progressive myopia are affecting more and more people worldwide. This has led to a big effort by industry and optometry experts to expand diagnostic and management options. With a projected prevalence of 50 percent of the world’s population by 2050*.

ZEISS is therefore combining more than ten years of extensive experience with progressive and high myopia in Asia with scientifically-based findings to offer effective, specific myopia management solutions in Europe as well.

ZEISS MyoCare lenses: Efficacy and relaxed, good vision in one lens     

Various methods have been developed and tested for managing the progression of myopia, including eyeglasses, contact lenses, and eye drops. ZEISS focuses on comprehensive myopia management, of which innovative spectacle lenses are an important component. ZEISS MyoCare is a new, clinically-proven, effective spectacle lens design that incorporates more than ten years of ZEISS myopia management practice, including special spectacle lenses and scientific insights into the use of contact lenses in orthokeratology.

The latest generation of myopia spectacle lenses uses microstructures to create a simultaneous competing defocus in the peripheral areas. Around the center of the lens with far distance correction, the functional zone incorporates almost invisible concentric circles with alternating defocus and correction zones expanding towards the periphery of the lens. The peripheral defocus which is achieved in this way has been shown to effectively delay the growth of the eye’s length beyond that which is physiologically normal, thus slowing down the progression of myopia.

Together with a leading myopia management institute, Wenzhou Medical University Eye Hospital WMU, China, ZEISS tested different design variants. The MyoCare design, as the most promising of the tested designs, is patented as “Cylindrical Annular Refractive Elements” or C.A.R.E. Technology. To avoid hyperopic defocus for all directions of gaze, ZEISS MyoCare uses a second, innovative technology: ClearFocus optimizes the free-form back of the lens point by point.

ZEISS MyoCare is being tested together with various clinical partners in randomized clinical studies involving more than 1,000 children. The first 12-month interim results of a long-term study with Wenzhou Medical University Eye Hospital demonstrate evidence of efficacy through an absolute reduction in myopia progression in line with study expectations.

“Progressive myopia requires a particularly high sense of responsibility because its professional management sets the course for vision as an essential prerequisite for children’s development,” says Dr. Ohlendorf. Research and collaboration with universities and other international scientific institutions and eye clinics will therefore continue to be an essential part of ZEISS’s efforts in making further developments in myopia management.

To find this optimum balance, we tested more than a dozen prototypes with varying combinations of lens design parameters in a kind of pre-clinical study together with the Wenzhou Medical University Eye Hospital: we first tested the subjective wearability and visual performance with myopic test wearers. The most promising prototypes were then handed out to a small cohort of Chinese children to test the lens prototypes in a real-life wearer trial. The children wore the test lenses for several days in their daily life and again, wearability and visual acuity was assessed to evaluate the subjective visual performance of the lens designs. Based on this evaluation, the prototypes with the optimal combination of vision correction, wearability, and adaptation plus the highest ratings of satisfaction and that were overall most promising with regards to their clinical efficacy were selected for clinical testing in the RCT. These two lens design variants, ZEISS MyoCare and ZEISS MyoCare S representing a harder and a softer version of the ZEISS MyoCare lens design received likewise good evaluations in pre-clinical testing and were therefore subjected to assess their safety and effectiveness in the clinical trials.

ZEISS has launched its first-ever, age-related myopia management lens solution. ZEISS MyoCare lenses are recommended for children younger than 10 years of age and ZEISS MyoCare S lenses are recommended for children age 10 years and older.

ZEISS MyoCare and MyoCare S lenses are the first age-related myopia management lens solution available with ZEISS  Premium coatings, and  ZEISS UVProtect Technology for full UV protection.** Which is an enhancement of the portfolio and our unwavering commitment to research and development” explains Bryan Rossi, the President of Zeiss Vision Care Canada.

To learn more, click HERE

Click HERE for the press release.

This post is sponsored by ZEISS Canada.

*Correction: Regarding myopia prevalence we corrected the reference year into 2050. **Not all products are available in all markets.

Boasting elegance and sophistication, SI-5028 is a beautifully designed modified round frame. Crafted entirely from Titanium, it is both lightweight and hypoallergenic. Clean and sleek, its elevated design features stunning cut-outs and twisted temples, a true hallmark of Stepper’s DNA.

Distributed by: www.westgroupe.com

Two recently presented studies provide additional evidence to support why more than 175,000 age-appropriate children worldwide are successfully wearing CooperVision MiSight^® 1 day soft contact lenses for myopia control. New research focused on distance vision and image quality complements the international, multi-site, seven-year clinical trial that demonstrated sustained slowing of eye growth and evidence indicates that there is no rebound effect for the innovative intervention.

“With myopia management now the standard of care in Canada, it’s critical that children have an outstanding first experience when receiving treatment. CooperVision has proven MiSight^® 1 day’s effectiveness of slowing the progression of myopia through unequaled long-term research. Now we are giving eye care professionals even more prescribing confidence by reinforcing its visual performance,” said Elizabeth Lumb, BSc (Hons) MCOptom, FBCLA, Director of Global Professional Affairs, Myopia Management, CooperVision.

Short Term Visual Performance of Two Myopia Control Soft Contact Lenses (Guthrie S., et al.) enrolled 26 neophyte children ages 8-15 in a double masked, single visit, non-dispensing trial where MiSight^® 1 day and ACUVUE^® Abiliti^™ 1-Day lenses were fit and worn contralaterally for one hour in randomized eyes. Children in MiSight^® 1 day rated their subjective vision distance as significantly higher and showed significantly better distance visual acuity. Among children who expressed a lens preference based on vision, more than 90% chose MiSight^® 1 day. Managed by the Centre for Ocular Research & Education (CORE), the study was presented at the 2023 BCLA Clinical Conference & Exhibition.

A separate study examined the optical designs of the same two lenses to better understand clinical reports of MiSight^® 1 day’s superior image quality. Image Quality Characterization of Myopia Control Contact Lens Designs (Richards J., et al.) computed point spread functions, image quality, and simulated retinal images for a model young eye for a range of pupil sizes. Researchers found that the combined effects of the blur circles from ACUVUE^® Abiliti^™ 1-Day’s central +10D coaxial zone and its non-coaxial rings introduced image degradation across the entire pupil range.The MiSight^® 1 day lens, which is designed with a dedicated, clear vision central zone, ensures high image quality. The investigation was conducted by Indiana University and presented at the 2023 Association for Research in Vision and Ophthalmology (ARVO) Annual Meeting.

MiSight^® 1 day is the first and only soft contact lens approved by the U.S. FDA and China NMPA to slow the progression of myopia in children aged 8-12 at the initiation of treatment. CooperVision also offers a range of orthokeratology designs and spectacles with Diffusion Optics Technology^™ for myopia management, which are currently available in select markets.

Click HERE for the full press release and references.

Ray-Ban and Ferrari join forces once again to create classic styles inspired by premium details of the legendary F1 car. Featuring innovative, state-of-the-art racing materials and Scuderia Ferrari design, the collection brings a touch of elegance to casual shapes with double bridge constructions, premium carbon fiber aviator, bold car inspired details and new dedicated temples.

The Ray-Ban for Scuderia partnership has continued to reinforce Ray-Ban’s positioning as the eyewear brand of Formula 1 through North American a Miami activation in May and now Montreal for the upcoming Grand Prix. They will celebrate the partnership through a consumer activation showcasing the collection on Peel St during race week.

Ray-Ban has secured a container in partnership with New Look Vision Group that features two high-fidelity racing simulators where guests can race each other in real time. Each day, a grand prize will be awarded to the fastest driver of the day while all attendees are encouraged to view and shop the full collection in the booth.

Join the team on Friday, June 16 to view the event and see how leveraging the sponsorship creates a uniquely powerful market position that generates excitement through all Canadian accounts open to the collection.

SAINZ AND LECLERC RACE THE MONTREAL GRAND PRIX ON JUNE 18TH!

Montreal, QC – Location: Corner of Peel Street and Sainte-Catherine Street West

Date: June 15– 18

Click HERE for the full press release.